Trevi Therapeutics Inc (TRVI) concluded trading on Thursday at a closing price of $6.17, with 2.96 million shares of worth about $18.28 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 131.95% during that period and on June 12, 2025 the price saw a loss of about -1.28%. Currently the company’s common shares owned by public are about 99.89M shares, out of which, 69.87M shares are available for trading.
Stock saw a price change of -8.46% in past 5 days and over the past one month there was a price change of -4.42%. Year-to-date (YTD), TRVI shares are showing a performance of 49.76% which increased to 143.87% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.36 but also hit the highest price of $7.48 during that period. The average intraday trading volume for Trevi Therapeutics Inc shares is 1.76 million. The stock is currently trading -3.16% below its 20-day simple moving average (SMA20), while that difference is down -2.12% for SMA50 and it goes to 38.35% higher than SMA200.
Trevi Therapeutics Inc (NASDAQ: TRVI) currently have 99.89M outstanding shares and institutions hold larger chunk of about 43.98% of that.
The stock has a current market capitalization of $735.12M and its 3Y-monthly beta is at 0.53. It has posted earnings per share of -$0.45 in the same period. It has Quick Ratio of 15.38 while making debt-to-equity ratio of 0.01. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for TRVI, volatility over the week remained 4.78% while standing at 4.42% over the month.
Stock’s fiscal year EPS is expected to rise by 7.67% while it is estimated to decrease by -26.55% in next year. EPS is likely to shrink at an annualized rate of -13.45% for next 5-years, compared to annual growth of 27.09% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on May 28, 2025 offering a Buy rating for the stock and assigned a target price of $21 to it. Coverage by Raymond James stated Trevi Therapeutics Inc (TRVI) stock as a Strong buy in their note to investors on March 10, 2025, suggesting a price target of $29 for the stock. On March 10, 2025, Needham Reiterated their recommendations, while on December 12, 2024, H.C. Wainwright Reiterated their ratings for the stock with a price target of $7.50. Stock get an Outperform rating from Leerink Partners on September 09, 2024.
